BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38200576)

  • 1. Validation and interpretation of Pan-TRK immunohistochemistry: a practical approach and challenges with interpretation.
    Karakas C; Giampoli EJ; Love T; Hicks DG; Velez MJ
    Diagn Pathol; 2024 Jan; 19(1):10. PubMed ID: 38200576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
    Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
    Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-TRK Immunohistochemistry Is Highly Correlated With NTRK3 Gene Rearrangements in Salivary Gland Tumors.
    Csanyi-Bastien M; Lanic MD; Beaussire L; Ferric S; François A; Meseure D; Jardin F; Wassef M; Ruminy P; Laé M
    Am J Surg Pathol; 2021 Nov; 45(11):1487-1498. PubMed ID: 33899788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-tropomyosin receptor kinase immunohistochemistry is a feasible routine screening strategy for NTRK fusions in mismatch repair-deficient colorectal carcinomas.
    Zhang Z; Pang J; Chen L; Chen J; Li J; Liu H; Wang J; Wu H; Liang Z
    Hum Pathol; 2022 Nov; 129():21-31. PubMed ID: 35977594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing.
    Koehne de González A; Mansukhani MM; Fernandes H; Hsiao SJ
    Cancer Genet; 2022 Apr; 262-263():47-52. PubMed ID: 35007853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
    Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A
    Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions.
    Brčić I; Godschachner TM; Bergovec M; Igrec J; Till H; Lackner H; Scheipl S; Kashofer K; Brodowicz T; Leithner A; Szkandera J; Liegl-Atzwanger B
    Mod Pathol; 2021 Feb; 34(2):396-407. PubMed ID: 32860002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting ETV6-NTRK3 fusion.
    Xu B; Haroon Al Rasheed MR; Antonescu CR; Alex D; Frosina D; Ghossein R; Jungbluth AA; Katabi N
    Histopathology; 2020 Feb; 76(3):375-382. PubMed ID: 31448442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using pan-TRK and RET Immunohistochemistry for the Detection of Fusion Types of Salivary Gland Secretory Carcinoma.
    Su YJ; Lee YH; Jin YT; Hsieh MS
    Appl Immunohistochem Mol Morphol; 2022 Apr; 30(4):264-272. PubMed ID: 35384876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemistry with a pan-TRK antibody distinguishes secretory carcinoma of the salivary gland from acinic cell carcinoma.
    Hung YP; Jo VY; Hornick JL
    Histopathology; 2019 Jul; 75(1):54-62. PubMed ID: 30801752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Pan-TRK Antibody is a Sensitive and Specific Tool for the Detection of NTRK Fusion Genes.
    Bautista-Wong C; Mojica-González Z; Hop-Garcia K; Bornstein Quevedo L
    Appl Immunohistochem Mol Morphol; 2023 Apr; 31(4):213-216. PubMed ID: 37017998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The sensitivity of pan-TRK immunohistochemistry in solid tumours: A meta-analysis.
    Hondelink LM; Schrader AMR; Asri Aghmuni G; Solleveld-Westerink N; Cleton-Jansen AM; van Egmond D; Boot A; Ouahoud S; Khalifa MN; Wai Lam S; Morreau H; Bovee JVMG; van Wezel T; Cohen D
    Eur J Cancer; 2022 Sep; 173():229-237. PubMed ID: 35933886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors.
    Rudzinski ER; Lockwood CM; Stohr BA; Vargas SO; Sheridan R; Black JO; Rajaram V; Laetsch TW; Davis JL
    Am J Surg Pathol; 2018 Jul; 42(7):927-935. PubMed ID: 29683818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study.
    Van Bockstal MR; Beniuga G; Craciun L; Creytens D; Dedeurwaerdere F; Delvenne P; Demetter P; De Wiest B; Dewinne K; Habran L; Pauwels P; Theate I; Vander Borght S; Van Der Steen K; Weynand B
    Pathobiology; 2022; 89(6):393-406. PubMed ID: 35350025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3 fusion subtypes, and RET rearrangement in salivary secretory carcinoma.
    Yamamoto H; Nozaki Y; Sugii A; Taguchi K; Hongo T; Jiromaru R; Sato M; Nakano T; Hashimoto K; Fujiwara M; Oda Y
    Hum Pathol; 2021 Mar; 109():37-44. PubMed ID: 33301751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland.
    Bell D; Ferrarotto R; Liang L; Goepfert RP; Li J; Ning J; Broaddus R; Weber RS; El-Naggar AK
    Virchows Arch; 2020 Feb; 476(2):295-305. PubMed ID: 31423558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma.
    Strohmeier S; Brcic I; Popper H; Liegl-Atzwanger B; Lindenmann J; Brcic L
    Sci Rep; 2021 May; 11(1):9785. PubMed ID: 33963267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic comparison of pan-Trk immunohistochemistry assays among multiple cancer types.
    Haberecker M; Töpfer A; Melega F; Moch H; Pauli C
    Histopathology; 2023 Jun; 82(7):1003-1012. PubMed ID: 36759438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorescent In Situ Hybridization Must be Preferred to pan-TRK Immunohistochemistry to Diagnose NTRK3-rearranged Gastrointestinal Stromal Tumors (GIST).
    Castillon M; Kammerer-Jacquet SF; Cariou M; Costa S; Conq G; Samaison L; Douet-Guilbert N; Marcorelles P; Doucet L; Uguen A
    Appl Immunohistochem Mol Morphol; 2021 Sep; 29(8):626-634. PubMed ID: 33758144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter Harmonization Study of Pan-Trk Immunohistochemistry for the Detection of NTRK3 Fusions.
    Adam J; Stang NL; Uguen A; Badoual C; Chenard MP; Lantuéjoul S; Maran-Gonzalez A; Robin YM; Rochaix P; Sabourin JC; Soubeyran I; Sturm N; Svrcek M; Vincent-Salomon A; Radosevic-Robin N; Penault-Llorca F
    Mod Pathol; 2023 Aug; 36(8):100192. PubMed ID: 37084942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.